Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2024 Aug 15;19(8):e0307001. doi: 10.1371/journal.pone.0307001

Geographic information system and information visualization capacity building: Successful polio eradication and current and future challenges in the COVID-19 era for the World Health Organization’s African region

John Kapoi Kipterer 1,*, Kebba Touray 1, Akpan Ubong Godwin 1, Aboubakar Cisse 1, Babona Nshuti Marie Aimee 1, Ngobe Busisiwe 1, Chefor Ymele Demeveng Derrick 1, Green Hugh Henry 1, Ndoutabe Modjirom 1, Vince Seaman 2, Jamal Ahmed 1
Editor: Terna Ignatius Nomhwange3
PMCID: PMC11326561  PMID: 39146252

Abstract

Despite a half-century-long global eradication effort, polio continues to have a devastating impact on individuals and communities worldwide, especially in low-income countries affected by conflict or geographic barriers to immunization programs. In response, the World Health Organization (WHO) Global Polio Eradication Initiative (GPEI) employs disease surveillance and vaccination campaigns coordinated through the WHO Regional Office for Africa (AFRO) Geographic Information System (GIS) Centre. Established in 2017, the AFRO GIS Centre played a key role in the eradication of wild-type polioviruses (WPVs) in 2020, but the COVID-19 pandemic, emergence of circulating vaccine-derived polioviruses, and transmission of WPV1 from Central Asia have led to a resurgence of polio in Sub-Saharan Africa. The AFRO GIS comprises a set of mobile device or cloud-based tools for geospatial data collection, analysis, and visualization. Using tools such as Auto-Visual Acute Flaccid Paralysis Detection and Reporting, electronic surveillance, and Integrated Supportive Supervision, GIS personnel collect polio case numbers and locations, track field worker activities, follow the movements of nomadic populations vulnerable to polio and other diseases, and determine needs for further healthcare deployments. The system is location specific and operates in real time, enabling the AFRO GIS to promptly target its responses to polio, COVID-19, Ebola virus disease, and other public health crises and natural disasters. The present review describes the components of the AFRO GIS and how the AFRO GIS Centre coordinated on-the-ground polio eradication efforts to help secure Africa’s certification as WPV free. It also examines current and prospective challenges regarding other disease outbreaks in the COVID-19 era and how the AFRO GIS Centre is addressing these ongoing public health needs.

Introduction

Paralytic poliomyelitis (polio)—an incurable and potentially fatal disease—persists in pockets throughout the world, despite a global eradication effort underway for more than half a century [1, 2]. Wild-type polioviruses (WPVs) 2 and 3 were declared globally eradicated in 2015 and 2019, respectively [1], and the World Health Organization (WHO) African region was declared WPV2 free in 2020 [3]. In addition, the emergence of circulating vaccine-derived polioviruses (cVDPVs) has led to increasing case reports of acute flaccid paralysis (AFP)—the primary sign of polio infection—throughout the globe. Over 3000 polio cases have been reported worldwide since 2020, including nearly 700 cases in the 12 months prior to March 2023 (Fig 1) [4–6]. Although polio case counts are highest in low-income countries affected by war or geographic barriers to immunization programs, polio has also been detected in a growing number of middle- and high-income nations [6].

Fig 1. Global case counts of wild-type poliovirus 1 (WPV1) and circulating vaccine-derived polioviruses (cVDPVs) 1, 2, and 3 reported between 29 October 2022 and 30 October 2023.

Fig 1

Open in a new tab

Counts exclude viruses detected from environmental surveillance. Source: World Health Organization/HQ/Polio Eradication Program @2024 [6].

Over 95% of polio cases reported in 2022 were in African countries, including a small, but significant number caused by a Pakistani WPV1 lineage documented in Mozambique and Malawi [7], and a large majority caused by cVDPVs [6]. Vaccine-derived polio arises in underimmunized populations due to genetic instability of the live-attenuated viruses included in the oral polio vaccine (OPV). One of the strengths of OPV is that the attenuated virus can spread to unvaccinated contacts of vaccine recipients, immunizing them against polio and extending protection to the larger community. In areas with low vaccination rates, however, circulating OPV viruses sometimes mutate, reverting to neurovirulent cVDPV strains that produce paralysis similar to that seen in WPV infections [8, 9].

Interrupting transmission of both WPV1 and cVDPVs are the primary goals of the Polio Eradication Strategy 2022–2026 developed by the WHO Global Polio Eradication Initiative (GPEI) [10]. Along with developing partnerships with political entities and affected communities, the WHO GPEI uses a 2-pronged approach involving intensive disease surveillance and campaigns to boost vaccination coverage above 95% (the threshold at which cVDPV transmission is eliminated) [10, 11]. These tactics have successfully stopped past outbreaks, but the COVID-19 pandemic interfered with GPEI efforts, promoting a resurgence in polio cases [10]. The resurgence of WPV1 into the African continent and ongoing outbreaks of cVDPV infections highlights the need for highly coordinated and intensive polio surveillance and immunization efforts in Africa, including deployment of novel OPV type 2 (nOPV2), which reduces the risk of cVDPV2 (the most common form of vaccine-derived polio) [10, 12]. The rollout of nOPV2 in the African region is aimed at addressing the outbreak of polio, strengthening immunization efforts, reducing the transmission of cVDPV2, and contributing to the efforts of the GPEI [13, 14]. This initiative represents a significant milestone in combating polio outbreaks, particularly in the countries of the Lake Chad Basin region, which have been significantly impacted by the disease [15]. The introduction of nOPV2 in Nigeria and Liberia is a crucial step towards effectively responding to the ongoing cVDPV2 outbreaks and preventing further transmission of the virus [16].

In Sub-Saharan Africa, with its limited access to geographic information system (GIS) infrastructure, coupled with inadequate technical and analytical skills [17], GPEI activities are coordinated through the WHO Regional Office for Africa (AFRO) GIS Centre. Since its establishment in 2017, the AFRO GIS Centre has played a vital role in achieving Africa’s WPV-free status. After the COVID-19 pandemic, the GIS Centre also supported the development of electronic tools for data collection, analysis, and monitoring that have been used not only in polio, but in COVID-19, Ebola virus disease, and other public health initiatives throughout the region [18].

This review describes the components of the WHO AFRO GIS and how the AFRO GIS Centre coordinated on-the-ground polio eradication efforts to help secure Africa’s certification as WPV free. It also examines current and prospective challenges in the COVID-19 era and how the GIS Centre is addressing these ongoing public health needs in Africa.

Geographic information system overview

In the generic sense, GIS is a computer system used to capture, store, verify, and display 3-dimensional location data, ie, data related to positions on Earth’s surface [19]. In the public health sphere, GIS is used to integrate and track data collected for environmental and disease outbreak surveillance, track field activities such as vaccination campaigns, and provide essential information on the movement and activities of field personnel [18, 20].

WHO AFRO geographic information system

The WHO AFRO GIS consists of multiple, mobile- and cloud-based software tools for geospatial data collection, analysis, and visualization, which support polio and other public health interventions at regional, national, and local levels in the African region [20]. These tools enable the WHO AFRO GIS Centre to address public health needs such as determining which regions need more healthcare workers, the location of vulnerable populations and their level of healthcare access, and the optimal deployment of mobile clinics [18]. Because GIS is location specific and operates in real time, it facilitates prompt and focused responses to health crises and natural disasters.

Solutions of the WHO AFRO geographic information system

Mapping and analytic software programs comprising the WHO AFRO GIS Centre’s solutions include Power BI (Microsoft, Redmond, Washington, USA), a business intelligence visualization tool; ArcGIS Online (Esri, Redlands, California, USA), an open data kit for mobile application tools, which is a cloud-based data mapping and collection program [21]; Vaccination Tracking System (VTS) [22]; and Geospatial Tracking System (GTS). The VTS and GTS are deployed to support the tracking of vaccination teams during polio outbreak campaigns. In addition, the AFRO GIS Centre, in collaboration with Novel-t (Geneva, Switzerland), uses GeoPoDe (Geographic, Population, & Demographic Data; Bill & Melinda Gates Foundation, Seattle, Washington), an open-source repository for geospatial reference data sets. GeoPoDe shows population data on topographic maps that also highlight the user’s choice of points of interest, such as settlements, schools, and health facilities (Fig 2), and can be used to support microplanning activities [23].

Fig 2. Screen capture from Ghana (northern region) GeoPoDe display showing location of health facilities and towns.

Fig 2

Open in a new tab

The data are obtained by WHO from the ministry of health and bureaus of statistics, and are incorporated in the GeoPoDe by the WHO in support of ministry of health decision-making. Source: Bill and Melinda Gates Foundation 2022 [23].

These tools permit GIS personnel to collect AFP case numbers and locations, and data for environmental surveillance, track field activities, and identify nomadic population settlements s. In addition, data collected by field personnel using mobile applications such as Auto-Visual AFP Detection and Reporting (AVADAR), electronic surveillance (eSURV), and Integrated Supportive Supervision (ISS) are used to not only identify suspected AFP cases and polio immunizations, but to determine needs for further healthcare service deployment (Figs 3 and 4) [24].

Fig 3. Auto-Visual AFP Detection and Reporting (AVADAR).

Fig 3

Open in a new tab

AFP, acute flaccid paralysis; CC, cluster consultant; CI, community informant; DSNO, Disease Surveillance Notification Officer; HF, health facility; HW, health worker; LGA, Local Government Area; ODK, Open Data Kit; SMS, short message service [25].

Fig 4. Electronic surveillance (eSURV).

Fig 4

Open in a new tab

AFRO, World Health Organization (WHO) Regional Office for Africa. Source: AFRO/GIS Centre 2024; Polio Eradication Program-African region.

Integrated Supportive Supervision and eSURV are mobile health solutions for effective supervision and surveillance in healthcare. Integrated Supportive Supervision utilizes electronic checklists on Android phones for active case finding and routine immunization supervision by the WHO and government staff [26]. Electronic surveillance ensures government surveillance agents conduct active searches using mobile phones in health facilities and communities [27]. Auto-Visual AFP Detection and Reporting is a community-based surveillance solution that employs the use of a mobile app combining visual, audio, and Short Message Service reporting to enhance AFP surveillance [25]. It aims to improve AFP case detection and reporting, enhance reporting timeliness, ensure “Zero” reporting of AFP cases, provide real-time case information, and increase community participation and ownership in surveillance efforts.

The data collected and stored in the WHO servers through these solutions are connected to ArcGIS Online and Power BI for analyses that involve mapping and visualizations, with program indicators of surveillance visualized in a dashboard. Visualization analytics are used by the program staff to identify gaps in surveillance, where areas not visited by active case search and routine surveillance personnel are quickly identified for action, while the AFP cases reported by AVADAR are also integrated in the AFP database for follow-up.

The WHO AFRO GIS Centre staff can also analyze country-level outbreak responses, surveillance, and immunization efforts in real time on a web-based dashboard (Fig 5) [18, 28]. Based on data and information collated from these multiple platforms, the AFRO GIS Centre develops information visualization platforms such as the Africa Rapid Response Team Hub to provide timely access to information for informed decision-making.

Fig 5. Chad Lake Basin nomad mapping dashboard.

Fig 5

Open in a new tab

Location data for nomadic populations are used in immunization planning to ensure healthcare workers are able to reach nomadic communities. Source: World Health Organization Regional Office for Africa Geographic Information System Centre [28].

WHO AFRO geographic information system capacity-building efforts: 2017–2022

2017–2019

Proof of concept for the application of GIS software to polio eradication programs was documented in multiple African nations prior to the WHO AFRO GIS Centre’s establishment in 2017 [22, 29, 30]. To build on these successes, the AFRO GIS Centre was established to ensure proper national adoption of GIS, build the required capacity in relevant knowledge areas at all levels throughout Africa, and support regional and national interventions in surveillance, routine immunization, supportive immunization activities, information management, monitoring, and evaluation and accountability of teams and individuals at all levels [20]. To achieve these goals, the AFRO GIS Centre rolled out a series of train-the-trainer initiatives consisting of regional, in-person workshops intended to teach GIS focal points (ie, national health ministry officials and data managers, as well as the WHO data management representative in each country) how to use GIS for field data collection, management, and visualization, and deploy GIS resources locally. Initially, AFRO GIS Centre efforts were directed toward polio eradication in Africa. After WPV-free certification was achieved, AFRO GIS Centre initiatives were focused on improving African member states’ ability to use AFRO GIS Centre resources to address cVDPV outbreaks, Ebola, COVID-19, and other emerging crises.

After the WHO AFRO GIS Centre was established, use of GIS mobile applications in community-based surveillance activities such as AVADAR, and surveillance active cases such as eSURV and ISS helped close gaps in polio surveillance and immunization in several high-risk areas, including communities in Burkina Faso, the Lake Chad region, Mali, and Niger [20]. One of the most dramatic AFRO GIS Centre successes involved improving polio surveillance and immunization coverage in the remote Lake Chad region [20, 31]. The WHO AFRO GIS teams from Niger successfully vaccinated >200,000 children from Lake Chad island communities that had frequently been left out of previous surveillance and immunization efforts [31–34]. In addition in 2019, an estimated 3%–5% of African WPV cases occurred in ~35,000 nomads living in the Lake Chad Basin, which includes territory belonging to Cameroon, Central African Republic, Chad, Niger, and Nigeria. Using GIS mobile data collection tools, field personnel were able to identify specific nomadic groups, document their movements, and conduct AFP case surveillance to support planning and decision-making [20]. In the past 3 years despite numerous challenges, including armed conflicts in the region, >40,000 children in 3451 nomad camps representing 13 ethnic groups in 62 high-risk districts have been immunized against polio and other communicable diseases. These groups continue to be monitored and evaluated (Fig 5) [18].

Despite these successes, a 2019 survey assessing GIS adoption by the 47 WHO AFRO member states revealed deficiencies in GIS capacity throughout the continent. As shown in Fig 6, most countries lacked updated health facility master lists (comprehensive listings of the names, locations, and types of health facilities in each country); adequate office space or resources for GIS personnel, equipment, or software; or sufficient GIS staffing or training [20]. Where GIS training was provided, it failed to reach frontline workers. In addition, approximately 90% of GIS training required travel, 24% of which was international.

Fig 6. Selected findings from 2019 national assessment of geographic information system (GIS) adoption in Africa (n = 47 World Health Organization African Region member states) [20].

Fig 6

Open in a new tab

A: Survey responses from WHO AFRO GIS country teams regarding documentation of healthcare facility locations; provision of office resources for GIS staff, equipment, and software; and availability of trained GIS staff. Survey questions focused on geographic details, personal information, foundations of GIS, baseline data and standards, capacity building, services and applications, evaluation, challenges of GIS implementation, and lessons learned. B: Types of staff trained and instructional methods used in countries where GIS training was provided in last 2 years.

During an October 2019 meeting of the AFRO GIS Summit in Brazzaville, Republic of the Congo, representatives of the 47 member states reviewed WHO AFRO GIS Centre activities and identified barriers to polio eradication progress, including poor coordination between the WHO and national health ministries, inadequate preparedness of local health workforces for GIS, lack of interoperability, and inadequate sustainable financing [20]. To address the identified gaps and barriers, summit participants developed a list of recommendations for individual WHO AFRO member states and the AFRO GIS Centre (Table 1).

Table 1. Summary of key recommendations for WHO member states and WHO from the 2019 African Regional GIS Summit [20].
WHO MEMBER STATES WHO
• Foster interministry collaboration to ensure sharing of information and resources, and develop comprehensive and all-inclusive digital-health strategies
• Integrate GIS into country policies, strategies, and action plans
• Ensure health-system stakeholders and partners share outputs of their activities, and are aware of and have access to GIS
• Support interoperability, information sharing, and decentralized data management to ensure availability and accuracy of GIS to be used in emergencies
• Develop and regularly update master lists of health facilities and population settlements
• Maintain maps with up-to-date subnational boundaries
• Determine definitions and levels of health facilities, and treatment and service-delivery sites		 • Provide technologic and technical support to member states on data management and information use, and national strategies, plans, funding, and GIS implementation
• Develop and foster mentorship programs to facilitate dissemination of GIS-related knowledge and resources
• Provide guidance and documentation on GIS tools and systems
• Develop workspace for data collection, validation, and sharing
• Develop repository of minimal sets of standards and standard operating procedures
• Develop platform for member states and partners to document and share experiences, success stories, and details of GIS-related national projects and innovative technologies
Open in a new tab

GIS, geographic information system

2019 to present

Since the AFRO GIS Summit, GIS training and software capabilities have been updated and extended. The WHO/AFRO GIS Centre staff train data managers from ministries of health and WHO country offices, who, in turn, cascade the training to the subnational level, ie, district-level staff. Train-the-trainer workshops now are conducted to fulfil the following objectives:

  • Train participants as the trainers of trainers so that they can develop relevant content for country-level training and support;

  • Build the capacity of participants in the use of the Power BI visualization tool and ArcGIS Online mapping software for standard and quality map production for country programs and outbreak response;

  • Train participants on web-mapping applications provided in ArcGIS Online tools for dynamic mapping to improve information dissemination for decision-making;

  • Orient participants on the use of WHO AFRO GIS Centre innovative solutions and platforms, including GeoPoDe; and

  • Train participants on the use of the open data kit and ArcGIS Survey 123 to create maps and other survey tools, and deploy them in AFRO GIS Centre-managed servers

In addition, GIS training provides instruction on tools developed to support nOPV2 deployment and polio surveillance data analysis, including outbreak/cluster analysis and campaign coverage estimation. Trainees learn about the collection, validation, and use of geospatial reference datasets and polio spatial data used in AFP case and environmental surveillance, as well as immunization campaigns and nomadic population tracking. They are also provided with an introduction to spatial data analysis, the principles of spatial epidemiology, and the use of GTS for outbreak response campaigns and other activities.

After the latest series of GIS capacity-building workshops held over the first 6 months of 2022, the GIS network now consists of >120 GIS focal points across 45 of 47 countries in the WHO African region and >200 health ministry workers have been trained on GIS-related mobile health skills. In addition, 20 African nations (18 WHO AFRO member states) have made their population and demographic data available on GeoPoDe based on 2020 WorldPop datasets [23, 35]. The WHO AFRO GIS enables frontline workers to promptly alert health ministries of potential disease outbreaks based on real-time data from active AFP surveillance visits and environmental sampling. The latter, which involves the systematic sampling of sewage and testing for the presence of WPVs and cVDPVs, has been growing in importance as an early warning system for impending outbreaks, as it may allow the detection of poliovirus in a community before any AFP cases are reported [36]. When alerted to a potential outbreak, health ministry officials can use GIS to evaluate surveillance data alongside population estimates and locations, and track response team movement and activities, including in real time [5]. When alerted of an outbreak, WHO rapid response teams mobilize to affected areas within 48–72 hours [24]. Thus, the AFRO GIS provides WHO focal points with the means of more rapidly and efficiently implementing the WHO outbreak response, including the deployment of nOPV2 where appropriate.

Use of the WHO AFRO geographic information system beyond polio

The integration of polio transition processes involves the bringing together of various stakeholders and resources to ensure a smooth and effective transition. This includes integrating polio surveillance systems into existing disease surveillance networks, incorporating polio vaccinations into routine immunization programs, and merging the expertise and infrastructure developed for polio eradication with broader public health initiatives [37]. During the COVID-19 pandemic, WHO AFRO GIS Centre systems such as eSURV and ISS were repurposed for COVID-19 surveillance and contact tracing. The modified systems included contact-tracing capabilities, in addition to surveillance data collection specific to the identification of SARS CoV-2 infections; collected data could be viewed and analyzed using visualization platforms to provide health officials with actionable insights. After a pilot program conducted between April and June 2020, the COVID-19 contact-tracing application was initially deployed in Benin, Cameroon, Nigeria, South Sudan, Uganda, and Zimbabwe. A surveillance application designed for use in health facilities was adopted by 27 Sub-Saharan African countries. Because health officials were already familiar with GIS for polio surveillance, minimal training was required for COVID-19 application. In addition, the platform was designed to allow connectivity with existing contact-tracing and facility-based surveillance systems [38]. In Niger, integration of the ISS system with the COVID-19 contact-tracing application enabled remote education of frontline workers on COVID-19 recognition and safety protocols, in addition to the detection of COVID-19 cases and contact tracing in the community [39]. Environmental sampling for SARS-CoV-2 is also an important early detection tool for potential COVID-19 outbreaks that could be facilitated using GIS resources [40].

Another important effort currently underway is the development of a shared, centralized WHO AFRO geodatabase that will include information on health facilities, administrative boundaries, environmental and disease surveillance sites and data, and other GIS information in a centralized portal. For example, the WHO AFRO GIS is working with member states’ ministries of health to create a consolidated health facility master list for AFRO. When WHO field staff conduct immunizations or investigate infectious disease cases reported at health facilities or traditional healer sites, they collect location data for those sites (eg, name, location, and type of facility) through use of the eSURV and ISS mobile application. The inclusion of traditional healers in the master list is an important component of polio disease surveillance because they provide healthcare to most Africans, especially in rural areas [41]. The WHO AFRO GIS Centre will incorporate the collected information into health facility lists provided by each country’s ministry of health to update and validate the data in the GIS health facility master list. When complete, the health facility master list will exist as a living document and resource for WHO staff and their partners in each AFRO member state.

Future outlook on WHO AFRO geographic information system capacity

To address ongoing needs for GIS software development, support, and training, the WHO has partnered with Esri (the developer of ArcGIS) and other groups. These partnerships will facilitate not only training on GIS software, but also continue to lead to improved automated mapping support, data visualization, and analysis tools. In addition, the WHO-Esri collaboration will facilitate the development of advanced training modules covering advanced analytics for statistics and spatial analysis.

Ongoing efforts to improve WHO AFRO GIS capabilities include the need to ensure adequate GIS server capacity. The lack of dedicated servers at the country level was one of the largest gaps identified during the 2019 AFRO GIS Summit [20]. As GIS software continues to evolve, incorporating more layered and complex datasets, the need for a robust hardware infrastructure to support data visualization and processing will continue to grow. Addressing the need for server capacity is one of the most important goals for the future. To streamline GIS and capacity building efforts across the WHO African region, the WHO AFRO GIS Centre initiated intercluster GIS collaboration for all clusters, and a GIS working group is being established with a secretariat to sustain and strengthen collaboration around GIS infrastructure capacity building and baseline data development.

Conclusion

Geographic information systems are powerful decision-support tools for public health and were integral to the eradication of WPVs in Africa. The reemergence of WPV1 and continued outbreaks of cVDPVs, as well as gaps in immunization coverage, however, call for strengthening surveillance and implementing high-quality vaccination campaigns to achieve polio eradication. The WHO AFRO GIS Centre will continue to improve GPEI capacity in terms of trained personnel, and systems support and integration, with the goal of faster detection and response to polio and other disease outbreaks in the COVID-19 era.

Data Availability

The data that support the findings of this study are openly available from the WHO/AFRO GIS Centre at: https://afro-gis-center-who.hub.arcgis.com/pages/training, https://geopode.world/ and https://who.maps.arcgis.com/apps/dashboards/4d1662750a4849b0af606cd83b662938#mode=edit. The authors confirm that the data supporting the findings of this study are available within the article.

Funding Statement

Funding for the WHO AFRO GIS is provided by the World Health Organization, Geneva, Switzerland, and Bill & Melinda Gates Foundation, Seattle, Washington, USA. The Bill & Melinda Gates Foundation provided human resource support during the trainings. Both funders were involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript.

References

Decision Letter 0

Terna Ignatius Nomhwange

2 Nov 2023

PONE-D-23-21989Geographic information system and information visualization: past successes and future challenges in capacity building for the World Health Organization’s African regionPLOS ONE

Dear Dr. Kipterer,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 17 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Terna Ignatius Nomhwange, MD,DTM&H,MBA

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

"Funding for the WHO AFRO GIS is provided by the World Health Organization, Geneva, Switzerland, and Bill & Melinda Gates Foundation, Seattle, Washington, USA."

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

"Editorial support was provided by Amanda Justice and Geoff Marx of BioScience Communications, New York, New York, USA, funded by the Bill & Melinda Gates Foundation, Seattle, Washington, USA."

Funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"Funding for the WHO AFRO GIS is provided by the World Health Organization, Geneva, Switzerland, and Bill & Melinda Gates Foundation, Seattle, Washington, USA."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

5. We note that Figures 1 to 3 in your submission contain map/satellite images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

(1) You may seek permission from the original copyright holder of Figures 1 to 3 to publish the content specifically under the CC BY 4.0 license.  

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an ""Other"" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

(2) If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

Additional Editor Comments:

  • Please review and consider all the comments and suggestions by both reviewers to provide more clarity and context within the manuscript.

  • Both reviewers have also highlighted the focus on Polio in the current draft and the need to revise the title and text to reflect the aim of this review as stated in Lines 92-95? Is the manuscript about GIS and Polio alone or other diseases as well? You may revise the title of the manuscript accordingly showing "past" Polio Successes." and challenges "post covid" for GIS utilization for other disease outbreaks. Any examples of how the GIS system has supported any other diseases? (how is the AFRO GIS Centre addressing these ongoing public health needs?)

  • The current title also includes "capacity building". The conclusion is specific for Polio and GPEI, is this capacity building for WHO GIS Polio teams or for country field staff for Polio and other diseases as well?

  • In line with the recommendation on the title, please update the abstract and the conclusion to ensure alignments. Note also that the conclusion only mentions Polio and nothing about other diseases outbreaks.

  • Lines 169-171 documents polio vaccination by WHO AFRO GIS teams? Does the AFRO GIS deploy vaccination teams or is this by the teams recruited by the Governments? Is there a reference for this?

  • The section on use of GIS beyond Polio (Lines 245-276) is a clear example of Polio transition in action. Please include a line or two on Polio transition.

  • Please also revise to correct sentences and punctuations as may be required for consistency E.g.:  Line 215 & 21: Train (Orient) participants "on" while Line 219: Train participants "in".

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In summary this manuscript outlines the development and expansion of the use of GIS systems in the African WHO region for primarily polio eradication. This is a very important technological development both for polio eradication and future disease surveillance and intervention monitoring. The manuscript provides narrative of the progress to date, highlighting particular GIS gaps (i.e. it is not a scientific research article). However, to a reader not involved in this GIS network, more details are required to understand the processes. The authors also present data from a 2019 survey on national GID capacity but more details are required as to who was surveyed and whether follow-up data will be collected to measure progress. It would be much clearer if different visualisations were presented for a particular outbreak that the network has worked on e.g., The authors conclude the GIS system was important for achieving certification of WPV1 in the region, it would be helpful to see some examples of the different GIS layers that contributed to this.

Minor comments:

Abstract:

‘Currently, 95% of reported polio cases are in under-vaccinated populations’ it is not clear what you mean by this given many children will not have received type 2 OPV since 2016.

Introduction

Line 49, I think you mean WPV1 free?

Line 66, By vaccine-associated do you mean vaccine-derived?

Fig 1 why do you choose this specific time period?

The introduction would benefit with a few sentences describing withdrawal of type 2 from OPV in 2016 and the following declining immunity across the region, facilitating cVDPV2 spread. A little more detail required on the rollout of nOPV2 would help the reader.

Figure 2 – Requires more details in the legend – how is the data obtained? Which part of Nigeria is shown?

Paragraph 114 – ‘Components of the WHO AFRO geographic information system’. This section is hard to follow. Perhaps include a diagram to show if any of these platforms interact? More description required to understand what ISS, eSurv and AVADAR are – how do they interact with other GIS platforms? Perhaps show an example from each? It would be helpful to highlight in the diagram what new spatial data is the GIS Centre helping to collect compared to visualising standard surveillance data. It is not clear what PowerBI is used for and what ARC GIS is used for.

Figure 3– what data is going into this dashboard? How are nomadic populations ‘tracked’ it could be interpreted as unethical tracking of certain people so please explain.

Figure 4 – what is the y axis? % missing or having. Please provide more details on the survey – questions in the appendix? Who participated?

Train the trainer – who are these trainers, how are they located across countries? Who are those being trained?

Line 232 – population and demographic data – based on what data source? Most recent census or other?

Line 262 Consolidated health facility master list – this is a very exciting development. Is it possible to report on how complete this database is? What are the barriers to obtaining more data etc? What proportion of countries have supplied data….

IPV – has the GIS Centre been involved in evaluating the (few) IPV campaigns?

Reviewer #2: Authors should align the title, the main text and the conclusion and recommendations of this paper. The paper in its current form seems to be too much focused on polio even though its intention is to highlight the application ion WHO AFRO GIS tool in prevention and control of not only polio but other diseases.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PLOS ONE GIS.docx

pone.0307001.s001.docx (13.1KB, docx)
PLoS One. 2024 Aug 15;19(8):e0307001. doi: 10.1371/journal.pone.0307001.r002

Author response to Decision Letter 0

28 Feb 2024

Response to Reviewer/Editor Comments

PONE-D-23-21989

Geographic information system and information visualization: past successes and future challenges in capacity building for the World Health Organization’s African region

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Done.

2. Thank you for stating the following financial disclosure:

"Funding for the WHO AFRO GIS is provided by the World Health Organization, Geneva, Switzerland, and Bill & Melinda Gates Foundation, Seattle, Washington, USA."

Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Response: Please add the following text re the role of the funder: “The Bill & Melinda Gates Foundation provided human resource support during the trainings. Both funders were involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript.”

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"Editorial support was provided by Amanda Justice and Geoff Marx of BioScience Communications, New York, New York, USA, funded by the Bill & Melinda Gates Foundation, Seattle, Washington, USA."

Funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"Funding for the WHO AFRO GIS is provided by the World Health Organization, Geneva, Switzerland, and Bill & Melinda Gates Foundation, Seattle, Washington, USA."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: Funding Statement should read as follows: “Funding for the WHO AFRO GIS is provided by the World Health Organization, Geneva, Switzerland, and the Bill & Melinda Gates Foundation. Editorial support was provided by Amanda Justice and Geoff Marx of BioScience Communications, New York, New York, USA, funded by the Bill & Melinda Gates Foundation.”

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Response: This has already been shared and data were downloaded: https://whonghub.org/faroukh/92/1537#/table (Username: faroukh; Password: Welcome12345). Text has been updated. [Lines 371-4]

5. We note that Figures 1 to 3 in your submission contain map/satellite images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

(1) You may seek permission from the original copyright holder of Figures 1 to 3 to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an ""Other"" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

(2) If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

Response: Figure 1 has been revised and does not require permission. Sources for Figures 1 and 4 have been added to legends. New Figures 2 and 5 (formerly 3) are derived from GeoPoDe, an open-source, public data repository for geospatial reference datasets, and does not require permission. However, we have requested and received permission to be safe. (Note: GeoPoDe is a public web data repository for geospatial datasets available by country. The platform allows public health officials and partner organizations to visualise geospatial data on an interactive map and download the data in multiple formats. All datasets contained in GeoPode are available to non-profit or humanitarian applications and are “operational” in nature. The datasets do not constitute authoritative, government-sanctioned reference data.)

Additional Editor Comments:

• Please review and consider all the comments and suggestions by both reviewers to provide more clarity and context within the manuscript.

Response: Done

• Both reviewers have also highlighted the focus on Polio in the current draft and the need to revise the title and text to reflect the aim of this review as stated in Lines 92-95? Is the manuscript about GIS and Polio alone or other diseases as well? You may revise the title of the manuscript accordingly showing "past" Polio Successes." and challenges "post covid" for GIS utilization for other disease outbreaks. Any examples of how the GIS system has supported any other diseases? (how is the AFRO GIS Centre addressing these ongoing public health needs?)

Response: The title has been revised: “Geographic information system and information visualization capacity building: successful polio eradication, and current and future challenges in the COVID-19 era.”

Examples of GIS applications in routine immunization to improve vaccination coverage in the Lake Chad region,and many WHO/AFRO countries are enumerated in an earlier publication: Akpan GU et al. Conclusions of the African Regional GIS Summit (2019): using geographic information systems for public health decision-making. BMC Proc 16 (Suppl 1), 3 (2022). https://doi.org/10.1186/s12919-022-00233-y.

• The current title also includes "capacity building". The conclusion is specific for Polio and GPEI, is this capacity building for WHO GIS Polio teams or for country field staff for Polio and other diseases as well?

Response: Capacity building is for polio and other diseases, as well. As noted, title has been revised.

• In line with the recommendation on the title, please update the abstract and the conclusion to ensure alignments. Note also that the conclusion only mentions Polio and nothing about other diseases outbreaks.

Response: We have revised the last sentence in the abstract (“It also examines current and prospective challenges regarding other disease outbreaks in the COVID-19 era and how the AFRO GIS Centre is addressing these ongoing public health needs.”) to address this issue [Lines 42-3]. The end of the Conclusion has been revised: “…with the goal of faster detection and response to polio and other disease outbreaks in the COVID-19 era.” [Line 363]

• Lines 169-171 documents polio vaccination by WHO AFRO GIS teams? Does the AFRO GIS deploy vaccination teams or is this by the teams recruited by the Governments? Is there a reference for this?

Response: It is the role of WHO/AFRO to respond through vaccination, and deployment is jointly made by WHO and the respective government. Additional references have been added. https://www.afro.who.int/health-topics/polio/polio-update-on-country-situations/nigeria-and-the-lake-chad-countries; https://polioeradication.org/countries/lake-chad-region/

• The section on use of GIS beyond Polio (Lines 245-276) is a clear example of Polio transition in action. Please include a line or two on Polio transition.

Response: We have added the following text: “The integration of polio transition processes involves the bringing together of various stakeholders and resources to ensure a smooth and effective transition. This includes integrating polio surveillance systems into existing disease surveillance networks, incorporating polio vaccinations into routine immunization programs, and merging the expertise and infrastructure developed for polio eradication with broader public health initiatives.” [Lines 291-5]

• Please also revise to correct sentences and punctuations as may be required for consistency E.g.: Line 215 & 21: Train (Orient) participants "on" while Line 219: Train participants "in".

[Note: HTML markup is below. Please do not edit.]

Response: Done

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

Response: Revisions made as specified in comments.

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

Response: N/A

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Response: Thanks

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Response: Thanks

Reviewer #1: In summary this manuscript outlines the development and expansion of the use of GIS systems in the African WHO region for primarily polio eradication. This is a very important technological development both for polio eradication and future disease surveillance and intervention monitoring. The manuscript provides narrative of the progress to date, highlighting particular GIS gaps (i.e. it is not a scientific research article). However, to a reader not involved in this GIS network, more details are required to understand the processes. The authors also present data from a 2019 survey on national GID capacity but more details are required as to who was surveyed and whether follow-up data will be collected to measure progress. It would be much clearer if different visualizations were presented for a particular outbreak that the network has worked on e.g., The authors conclude the GIS system was important for achieving certification of WPV1 in the region, it would be helpful to see some examples of the different GIS layers that contributed to this.

Response: There are no layers involved; it was achieved through surveillance visits, with evidence of visits at the health facility level with GPS enabled on submission of visit checklists. The use of GIS enables technologies in vaccination tracking systems and the use of the AVADAR electronic surveillance checklist serves as evidence (see: https://doi.org/10.29245/2578-3009/2021/S2.1101, http://dx.doi.org/10.16966/2471-8211.151, doi: 10.11604/pamj.supp.2022.42.1.33788, 10.2196/18950), https://doi.org/10.1186/s12889-018-6187-x).

Minor comments:

Abstract:

‘Currently, 95% of reported polio cases are

Attachment

Submitted filename: Kipterer PLOS1 Response 022824.docx

pone.0307001.s002.docx (42.1KB, docx)

Decision Letter 1

Terna Ignatius Nomhwange

27 Jun 2024

Geographic information system and information visualization capacity building: successful polio eradication and current and future challenges in the COVID-19 era for the World Health Organization’s African region

PONE-D-23-21989R1

Dear Mr.Kipterer

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Terna Ignatius Nomhwange, MD,DTM&H,MBA

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Acceptance letter

Terna Ignatius Nomhwange

2 Jul 2024

PONE-D-23-21989R1

PLOS ONE

Dear Dr. Kipterer,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Terna Ignatius Nomhwange

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: PLOS ONE GIS.docx

    pone.0307001.s001.docx (13.1KB, docx)
    Attachment

    Submitted filename: Kipterer PLOS1 Response 022824.docx

    pone.0307001.s002.docx (42.1KB, docx)

    Data Availability Statement

    The data that support the findings of this study are openly available from the WHO/AFRO GIS Centre at: https://afro-gis-center-who.hub.arcgis.com/pages/training, https://geopode.world/ and https://who.maps.arcgis.com/apps/dashboards/4d1662750a4849b0af606cd83b662938#mode=edit. The authors confirm that the data supporting the findings of this study are available within the article.

    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES